{"_id": "64fe7e2d1544b4d920499d05", "nctID": "NCT02862275", "booleanRepresentation": "{\n    \"$and\": [\n        {\n            \"$and\": [\n                {\"$or\": [\n                    {\"histologically confirmed malignancy\"},\n                    {\"pathologically confirmed malignancy\"}\n                ]},\n                {\"$or\": [\n                    {\"metastatic malignancy\"},\n                    {\"unresectable malignancy\"}\n                ]},\n                {\"$not\": {\"$or\": [\n                    {\"standard of care therapy exists\"},\n                    {\"standard of care therapy is effective\"}\n                ]}}\n            ]\n        },\n        {\"ACT infusion prior to study enrollment\"},\n        {\"$or\": [\n            {\"ACT with tumor infiltrating lymphocytes (TIL)\"},\n            {\"human leukocyte antigen (HLA)-class I T cell receptor (TCR)-engineered lymphocytes\"},\n            {\"HLA-class II TCR-engineered lymphocytes\"},\n            {\"chimeric antigen receptor (CAR)-engineered T cells\"}\n        ]},\n        {\"$and\": [\n            {\"prior ACT therapy completed\"},\n            {\"$or\": [\n                {\"radiographic progression of residual disease\"},\n                {\"active disease observed on biopsy\"}\n            ]}\n        ]},\n        {\"$or\": [\n            {\"$and\": [\n                {\"solid tumor patients\"},\n                {\"measurable disease\"},\n                {\"$or\": [\n                    {\"longest diameter \\>= 20 mm with conventional techniques\"},\n                    {\"longest diameter \\>= 15 mm with spiral CT scan, MRI, or calipers by clinical exam\"}\n                ]}\n            ]},\n            {\"$and\": [\n                {\"leukemia or non-Hodgkin's lymphoma patients\"},\n                {\"measurable disease according to revised response criteria for malignant lymphoma\"}\n            ]}\n        ]},\n        {\"disease suitable for assessment by pre- and post-biopsies\"},\n        {\"$not\": {\"$or\": [\n            {\"prior anti-programmed cell death (PD)-1 therapy\"},\n            {\"prior anti-PD-ligand (L)1 therapy\"},\n            {\"other immunotherapies\"}\n        ]}},\n        {\"$not\": {\"$and\": [\n            {\"prior anti-PD-1 therapy\"},\n            {\"prior anti-PD-L1 therapy\"},\n            {\"$not\": {\"$and\": [\n                {\"ACT completed\"},\n                {\"$not\": {\"residual disease documented\"}}\n            ]}}\n        ]}},\n        {\"$not\": {\"$or\": [\n            {\"ACT related toxicities resolved to grade 1\"},\n            {\"alopecia\"},\n            {\"vitiligo\"},\n            {\"endocrine abnormalities requiring replacement therapy (grade 2)\"}\n        ]}},\n        {\"$not\": {\"$or\": [\n            {\"prior other anti-cancer therapy for 28 days prior to atezolizumab administration\"},\n            {\"prior ACT therapy for 28 days prior to atezolizumab administration\"}\n        ]}},\n        {\"age \\>= 18 years\"},\n        {\"ECOG performance status =\\< 2\"},\n        {\"life expectancy > 3 months\"},\n        {\"absolute neutrophil count \\>= 1,000/mcL\"},\n        {\"platelets \\>= 75,000/mcL\"},\n        {\"$or\": [\n            {\"hemoglobin \\>= 8 g/dL\"},\n            {\"hemoglobin \\>= 8 g/dL\"}\n        ]},\n        {\"total bilirubin =\\< 1.5 x institutional upper limit of normal (ULN)\"},\n        {\"$or\": [\n            {\"aspartate aminotransferase (AST) =\\< 3 x ULN\"},\n            {\"alanine aminotransferase (ALT) =\\< 3 x ULN\"}\n        ]},\n        {\"$or\": [\n            {\"AST =\\< 5 x ULN for patients with liver involvement\"},\n            {\"ALT =\\< 5 x ULN for patients with liver involvement\"}\n        ]},\n        {\"creatinine clearance \\>= 30 mL/min/1.73 m^2 by Cockcroft-Gault\"},\n        {\"INR and aPTT =\\< 1.5 x ULN\"},\n        {\"$not\": {\"$or\": [\n            {\"therapeutic anticoagulation\"},\n            {\"INR and aPTT =\\< 1.5 x ULN\"}\n        ]}},\n        {\"$not\": {\"$or\": [\n            {\"adequate contraception for women of child-bearing potential and men\"},\n            {\"pregnant women\"}\n        ]}},\n        {\"ability to understand and willingness to sign a written informed consent document\"},\n        {\"$not\": {\"$or\": [\n            {\"chemotherapy or radiotherapy within 4 weeks prior to study entry\"},\n            {\"not recovered from adverse events due to agents administered more than 4 weeks earlier\"}\n        ]}},\n        {\"$or\": [\n            {\"hormone-replacement therapy or oral contraceptives\"},\n            {\"herbal therapy > 1 week prior to cycle 1, day 1\"},\n            {\"palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1\"}\n        ]},\n        {\"$and\": [\n            {\"prior treatment with anti-CTLA-4 antibody\"},\n            {\"$and\": [\n                {\"\\> 6 weeks from the last dose\"},\n                {\"$not\": {\"history of severe immune-related adverse effects from anti-CTLA-4 antibody\"}}\n            ]}\n        ]},\n        {\"$not\": {\"$or\": [\n            {\"treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1\"},\n            {\"treatment with systemic immunostimulatory agents within 6 weeks prior to cycle 1, day 1\"},\n            {\"treatment with systemic immunosuppressive medications within 2 weeks prior to cycle 1, day 1\"}\n        ]}},\n        {\"$or\": [\n            {\"$and\": [\n                {\"$not\": {\"acute, low dose, systemic immunosuppressant medications\"}},\n                {\"$not\": {\"inhaled corticosteroids and mineralocorticoids\"}},\n                {\"$not\": {\"low-dose supplemental corticosteroids for adrenocortical insufficiency\"}}\n            ]},\n            {\"bisphosphonate therapy for symptomatic hypercalcemia\"},\n            {\"$and\": [\n                {\"known primary central nervous system (CNS) malignancy\"},\n                {\"$not\": {\"asymptomatic untreated CNS disease\"}},\n                {\"$not\": {\"asymptomatic treated CNS metastases\"}}\n            ]}\n        ]},\n        {\"$not\": {\"$or\": [\n            {\"known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies\"},\n            {\"history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\"},\n            {\"known clinically significant liver disease\"},\n            {\"$not\": {\"past or resolved hepatitis B infection\"}},\n            {\"$not\": {\"hepatitis C virus (HCV) antibody negative or HCV RNA positive\"}},\n            {\"$not\": {\"history or risk of autoimmune disease\"}},\n            {\"$not\": {\"history of immune related events to anti-CTLA-4\"}},\n            {\"$not\": {\"controlled type 1 diabetes mellitus on a stable insulin regimen\"}},\n            {\"$not\": {\"eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only\"}}\n        ]}},\n        {\"$not\": {\"$or\": [\n            {\"history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan\"},\n            {\"active tuberculosis (TB)\"},\n            {\"$not\": {\"RANKL inhibitor therapy\"}},\n            {\"severe infections within 4 weeks prior to cycle 1, day 1\"},\n            {\"signs or symptoms of infection within 2 weeks prior to cycle 1, day 1\"},\n            {\"major surgical procedure within 28 days prior to cycle 1, day 1\"},\n            {\"administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1\"},\n            {\"uncontrolled intercurrent illness\"}\n        ]}},\n        {\"$not\": {\"$or\": [\n            {\"$not\": {\"previously tested positive for human immunodeficiency virus (HIV)\"}},\n            {\"$and\": [\n                {\"stable regimen of highly active anti-retroviral therapy (HAART)\"},\n                {\"$not\": {\"requirement for concurrent antibiotics or antifungal agents\"}},\n                {\"CD4 count above 250 cells/mcL\"},\n                {\"undetectable HIV viral load\"}\n            ]}\n        ]}},\n        {\"$not\": {\"pregnant women\"}}\n    ]\n}"}